Get started
Author

Juan García Burgos

Observed names: J. Garcia Burgos, Juan Garcia Burgos, Juan García-Burgos
Observed institution: European Medicines Agency
ORCID: 0009-0008-1298-1105
Observed ORCID: 0009-0008-1298-1105
OpenAlex ID: A5041558248
Better engagement, better evidence: working in partnership with patients, the public, and communities in clinical trials with involvement and good participatory practice
2025 · Nina Gobat, Catherine Slack, et al. · The Lancet Global Health · 68
Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future
2016 · Tomas Salmonson, Jean-Michel Dogné, et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 62
PDF
Sustaining Meaningful Patient Engagement Across the Lifecycle of Medicines: A Roadmap for Action
2021 · Maria Cavaller-Bellaubi, Stuart D. Faulkner, et al. · Therapeutic Innovation & Regulatory Science · 61
PDF
Artificial intelligence and real-world data for drug and food safety – A regulatory science perspective
2023 · Shraddha Thakkar, William Slikker, et al. · Regulatory Toxicology and Pharmacology · 55
Leveraging patient experience data to guide medicines development, regulation, access decisions and clinical care in the EU
2024 · Diogo Almeida, Denise Umuhire, et al. · Frontiers in Medicine · 31
Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop
2025 · Madeline Pe, Caroline Voltz-Girolt, et al. · The Lancet Oncology · 27
PDF
Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation
2018 · Efstratia Vatzaki, Sabine Straus, et al. · The Journal of Headache and Pain · 27
PDF
COVID‐19 vaccines: the importance of transparency and fact‐based education
2020 · Adam F. Cohen, Joop van Gerven, et al. · British Journal of Clinical Pharmacology · 26
Commentary on the European Medicines Agency's extended mandate: Protecting public health in times of crisis and improving availability of medicines and medical devices
2022 · Inga Abed, Rosa Gonzalez‐Quevedo, et al. · British Journal of Clinical Pharmacology · 11
Accelerating clinical trials in the EU (ACT EU): transforming the EU clinical trials landscape
2024 · Giacomo Capone, Björn Eriksson, et al. · Nature Reviews Drug Discovery · 10
European Medicines Agency seeks stakeholders' views on its reflection paper on patient experience data
2025 · Rosa Gonzalez‐Quevedo, Juan Garcia Burgos, et al. · British Journal of Clinical Pharmacology · 8
PDF
Biosimilar medicines: Why the science matters
2020 · Rosa Gonzalez-Quevedo, Elena Wolff-Holz, et al. · Health Policy and Technology · 8
Preparing for the incoming wave of biosimilars in oncology
2018 · Elena Wolff-Holz, Juan Garcia Burgos, et al. · ESMO Open · 8
PDF
The European Association of Urology Guidelines on Urological Infections: Bridging Regulatory Strategy with Proactive Clinical Leadership
2025 · Gernot Bonkat, Juan Garcia Burgos, et al. · European Urology Focus · 7
European Medicines Agency approvals of new medicines in September and October 2025
2025 · Bruno Sepodes, Juan Garcia Burgos, et al. · The Lancet Regional Health - Europe · 6
PDF
Stakeholders’ Understanding of European Medicine Agency’s COVID-19 Vaccine Information Materials in EU and Regional Contexts
2023 · Indiana Castro, Marie Van Tricht, et al. · Vaccines · 6
PDF
A Call To Prevent Inappropriate Prescribing of Fluoroquinolones from the European Medicines Agency and the European Association of Urology Guidelines Panel for Urological Infections
2025 · Juan Garcia Burgos, Eva Jirsova, et al. · European Urology · 4
A decade of collaboration in medicines regulation: healthcare professionals engaging with the European Medicines Agency
2024 · Ivana Silva, Giulia Gabrielli, et al. · Frontiers in Medicine · 4
Public information on shortages in the EU/EEA: improvements made between 2018 and 2020
2023 · Inga Abed, Juan Garcia Burgos, et al. · European Journal of Hospital Pharmacy · 4
PDF
European Medicines Agency approvals of new medicines in November and December 2025
2026 · Bruno Sepodes, Juan Garcia Burgos, et al. · The Lancet Regional Health - Europe · 3
PDF
The impact of the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) to address shortages of human and veterinary medicines across Europe
2025 · Inga Abed, Vanessa Bennett, et al. · Frontiers in Public Health · 3
PDF
Applying the EU Regulatory Framework to Determine the Benefit–Risk Profile of Psychedelics
2025 · Kate Browne, Ewa Bałkowiec-Iskra, et al. · ACS Pharmacology & Translational Science · 2
PDF
European medicines agency approvals of new medicines in January and February 2026
2026 · Bruno Sepodes, Juan Garcia Burgos, et al. · The Lancet Regional Health - Europe · 1
EMA approvals of new medicinal products and new biosimilar products in January and February 2025
2025 · Juan Garcia Burgos, Steffen Thirstrup · The Lancet Regional Health - Europe · 1
European Medicines Agency seeks stakeholders' views on future transparency measures for clinical trials
2023 · Rosa Gonzalez‐Quevedo, Laura Pioppo, et al. · British Journal of Clinical Pharmacology · 1
PDF
Works count: 39
Citation count: 444
H-index: 10
I10-index: 10
Year
Topic
Type